Chemistry:IBI311

From HandWiki
Revision as of 02:07, 6 February 2024 by Corlink (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.[1][2][3]

References

  1. ↑ "Innovent doses first patient in Phase III study of IBI311 for TED". Clinical Trials Arena. 8 May 2023. https://www.clinicaltrialsarena.com/news/innovent-first-patient-ted/. 
  2. ↑ "IGF Market And Pipeline Insights 2023" (in en). https://www.precisionbusinessinsights.com/market-reports/igf-market. 
  3. ↑ Li, Chen; Hao, Jun; Wang, Chuangshi; Yang, Jie; Zheng, Yitian; Zhang, Kuo; Hui, Wen; Meng, Xiangbin et al. (3 August 2023). "Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022". Drug Design, Development and Therapy 17: 2315–2324. doi:10.2147/DDDT.S409617. ISSN 1177-8881. PMID 37559911. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:IBI311&oldid=3333794"